pSivida Corp. (NASDAQ:PSDV) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders. |
On June27, 2017, pSivida Corp. (the Company) held a Special
Meeting of Stockholders (the Special Meeting). As of May10, 2017,
the record date for the Special Meeting, there were 39,356,999
shares of Common Stock issued and outstanding and entitled to
vote on the proposals presented at the Special Meeting, of which
28,696,440, or 72.91%, were present in person or represented by
proxy, which constituted a quorum. Set forth below are the final
voting results for each of the proposals submitted to a vote of
the Companys stockholders at the Special Meeting.
Proposal1. |
Ratification of the issuance of 5,100,000 shares of common stock to Australian Securities Exchange (ASX) Listing Rule 7.4 to refresh the Companys capacity to issue shares of common stock without prior stockholder approval to ASX Listing Rule 7.1. |
The Companys stockholders ratified the issuance by the Company
between March1, 2017 and May9, 2017 of 5,100,000 shares of Common
Stock (equivalent to 5,100,000 CHESS Depositary Interests) under
the At Market Issuance Sales Agreement the Company entered into
with FBR Capital Markets Co. dated February8, 2017, to a
registration statement filed by the Company with the U.S.
Securities and Exchange Commission (SEC), and the accompanying
prospectus supplement that the Company filed with the SEC on
February8, 2017. The voting on this proposal is set forth below:
For |
Against |
Abstain |
Non Votes |
|||
|
|
1,838,123 | 186,744 | 11,968,457 |
Proposal2. |
Amendment to the Companys Restated Certificate of Incorporation |
The Companys stockholders approved the adoption of an amendment
to the Companys Certificate of Incorporation, as amended, to
increase the number of authorized shares of Common Stock from
60,000,000 shares to 120,000,000 shares. The voting on this
proposal is set forth below:
For |
Against |
Abstain |
||
|
|
6,366,794 | 17,637 |
About pSivida Corp. (NASDAQ:PSDV)
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.